Yishen Tongluo formula alleviates diabetic kidney disease through regulating Sirt6/TGF-β1/Smad2/3 pathway and promoting degradation of TGF-β1

被引:22
作者
Zhang, Xiaowei [1 ,2 ]
Zhao, Liang [1 ,2 ]
Xiang, Shixie [1 ,2 ]
Sun, Yiran [1 ,2 ]
Wang, Pan [1 ,2 ]
Chen, Jenny Jie [3 ]
Teo, Brian Sheng-Xian [3 ]
Xie, Zhishen [1 ,2 ]
Zhang, Zhenqiang [1 ,2 ]
Xu, Jiangyan [1 ,2 ]
机构
[1] Henan Univ Chinese Med, Acad Chinese Med Sci, 156 Jinshui East Rd, Zhengzhou 450046, Peoples R China
[2] Major Chron Dis Chinese Med, Henan Engn Res Ctr Prevent & Treatment, 156 Jinshui East Rd, Zhengzhou 450046, Peoples R China
[3] Int Acad Affairs Dept Management & Sci Univ, Univ Dr,Sect 13,Off Persiaran Olahraga, Shah Alam 40100, Selangor, Malaysia
关键词
Yishen Tongluo formula; Diabetic kidney disease; Renal fibrosis; TGF-beta; 1; Sirt6; RENAL FIBROSIS; NEPHROPATHY; MECHANISMS; EXPRESSION; SMAD3;
D O I
10.1016/j.jep.2023.116243
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Yishen Tongluo formula (YSTLF) is formulated based on traditional Chinese medicine theory for the treatment of Diabetic kidney disease (DKD) and has been shown to be effective in improving the symptoms of DKD according to the clinical observation.Aim of the study: To explore the effect of YSTLF on DKD and figure out whether its effects were due to the regulation Sirt6/TGF-beta 1/Smad2/3 pathway and promoting degradation of TGF-beta 1. Materials and methods: The extract of YSTLF at 1, 2.5 and 5 g/kg was orally administered to C57BLKS/J (db/db) mice for 8 weeks and db/db mice were given valsartan as a positive control. The littermate db/m and db/db mice were given vehicle as the control and model group, respectively. Blood urea nitrogen and serum creatinine were detected and the urinary albumin excretion, urea albumin creatinine ratio was calculated. The histopathological change of renal tissues in each group was determined. Simultaneously, the levels of fibrosis-related proteins and messenger RNA (mRNA) in kidney and high glucose (HG)-induced SV40-MES-13 cells were detected. The roles of YSTLF in regulating of Sirt6/TGF-beta 1/Smad2/3 signaling pathway were investigated in HG-stimulated SV40-MES-13 cells and validated in db/db mice. Furthermore, the effect of YSTLF on TGF-beta 1 degradation was investigated in HG-stimulated SV40-MES-13 cells.Results: YSTLF significantly improved the renal function in DKD mice. YSTLF dose-dependently attenuated pathological changes and suppressed the expression of type I collagen, alpha smooth muscle actin, type IV collagen, and fibronectin in vitro and in vivo, resulting in ameliorating of renal fibrosis. YSTLF positively regu-lated Sirt6 expression, while inhibited the activating of TGF-beta 1/Smad2/3 signaling pathway. TGF-beta 1 was steady expressed in HG-stimulated SV40-MES-13 cells, whereas was continuously degraded under YSTLF treatment.Conclusions: YSTLF significantly ameliorates renal damages and fibrosis may via regulating Sirt6/TGF-beta 1/Smad2/ 3 signaling pathway as well as promoting the degradation of TGF-beta 1.
引用
收藏
页数:13
相关论文
共 36 条
[1]   Diabetic Kidney Disease Challenges, Progress, and Possibilities [J].
Alicic, Radica Z. ;
Rooney, Michele T. ;
Tuttle, Katherine R. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (12) :2032-2045
[2]   TGF-β signaling in renal disease [J].
Böttinger, EP ;
Bitzer, M .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (10) :2600-2610
[3]   The deacetylase sirtuin 6 protects against kidney fibrosis by epigenetically blocking β-catenin target gene expression [J].
Cai, Juan ;
Liu, Zhiwen ;
Huang, Xian ;
Shu, Shaoqun ;
Hu, Xiaoru ;
Zheng, Meiling ;
Tang, Chengyuan ;
Liu, Yu ;
Chen, Guochun ;
Sun, Lin ;
Liu, Hong ;
Liu, Fuyou ;
Cheng, Jinke ;
Dong, Zheng .
KIDNEY INTERNATIONAL, 2020, 97 (01) :106-118
[4]   Diabetes and nephropathy [J].
Caramori, ML ;
Mauer, M .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2003, 12 (03) :273-282
[5]   Transforming growth factor-β1 and diabetic nephropathy [J].
Chang, Albert S. ;
Hathaway, Catherine K. ;
Smithies, Oliver ;
Kakoki, Masao .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2016, 310 (08) :F689-F696
[6]   Diagnosis and Management of Type 2 Diabetic Kidney Disease [J].
Doshi, Simit M. ;
Friedman, Allon N. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (08) :1366-1373
[7]   Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins [J].
Frye, RA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 273 (02) :793-798
[8]   Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy [J].
Fujimoto, M ;
Maezawa, Y ;
Yokote, K ;
Joh, K ;
Kobayashi, K ;
Kawamura, H ;
Nishimura, M ;
Roberts, AB ;
Saito, Y ;
Mori, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 305 (04) :1002-1007
[9]  
Hathaway C.K., 2015, P NATL ACAD SCI US, V112
[10]   Role of tubule epithelial cells in the pathogenesis of tubulointerstitial fibrosis induced by glomerular disease [J].
Healy, E ;
Brady, HR .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1998, 7 (05) :525-530